 SAN DIEGO , March 28, 2022 PRNewswire -- Neurocrine Biosciences, Inc. Nasdaq: NBIX today announced that it will present new data on treatment patterns and unmet needs in adult and pediatric patients with classic congenital adrenal hyperplasia CAH at the Academy of Managed Care Pharmacy AMCP 2022 annual meeting in Chicago on March 29April 1. The three studies being presented evaluate the treatment patterns, healthcare-related costs, medication preferences, and unmet needs of patients with classic CAH. 